Results 51 to 60 of about 6,446 (159)

Coexistence of immunophenotypically normal and aberrant mast cells in patients with clonal mast cell diseases associates with more indolent subtypes and less severe disease characteristics

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Aberrant antigen expression on mast cells (MCs) is one of the most accurate diagnostic markers for clonal MC diseases (CMCD). Although the coexistence of normal and pathologic MCs is frequently seen, the disease characteristics associated with it have been minimally investigated.
Abdulrazzaq Alheraky   +6 more
wiley   +1 more source

Apigenin Protects Hypertensive Intracerebral Hemorrhage by Regulating Trx1 Through Binding to PRDX2

open access: yesPhytotherapy Research, Volume 40, Issue 11, Page 6276-6300, November 2026.
ABSTRACT Intracerebral hemorrhage (ICH) remains the most severe stroke subtype with high mortality and disability rates. Although apigenin has shown cerebroprotective potential in preclinical studies, its mechanism of action, particularly in hypertensive ICH, remains poorly understood.
Hao‐chen Xu   +6 more
wiley   +1 more source

Comprehensive mastocytosis data analysis from a single center

open access: yesBMC Cancer, 2023
Mastocytosis is a very rare disorder and is divided into three prognostically distinct variants by World Health Organization: Cutaneous mastocytosis (CM), systemic mastocytosis (SM), and mast cell sarcoma or localized mast cell (MC) tumors.
Tarık Onur Tiryaki   +11 more
doaj   +1 more source

Mastocitosis cutánea maculopapular infantil: reporte de un caso

open access: yesRevista Médica Clínica Las Condes, 2019
Resumen: Objetivo: Reportar un caso de mastocitosis cutánea maculopapular de inicio en la infancia y realizar una revisión bibliográfica con énfasis en el diagnóstico, estudio, pronóstico y tratamiento.
Renatta de Grazia   +3 more
doaj   +1 more source

Difficulties in diagnosis and management of mastocytosis in clinical practice and role of patients' associations [PDF]

open access: yesRomanian Journal of Medical Practice, 2017
Mastocytosis is a heterogeneous group of disorders characterized by abnormal expansion and accumulation of mast cells in one or more organs. It is a rare disease, with uncertain prevalence in many countries. The diagnosis and management of rare diseases,
Polliana Mihaela LERU, Dumitru MATEI
doaj   +1 more source

Safety of Venom Immunotherapy in Pregnancy: A Multicentre Study

open access: yesAllergy, EarlyView.
Venom immunotherapy (VIT) during pregnancy, when maintenance dose is well tolerated, can be continued. No increased risk of adverse effects to VIT or safety concerns for the pregnancy or the newborns were observed. No decreased efficacy of VIT, in case of re‐stings, was reported.
Matteo Martini   +20 more
wiley   +1 more source

Differential Roles for IL‐4Rα and IL‐13Rα1 in Immune Cell Infiltration and Epithelial Remodeling in Experimental Eosinophilic Gastritis

open access: yesAllergy, EarlyView.
This study described the development of an experimental model for eosinophilic gastritis (EoG). Experimental EoG recapitulates histopathological features of human disease. including foveolar elongation, fibrosis, eosinophilia, mastocytosis and shared transcriptional programs.
Anish Dsilva   +7 more
wiley   +1 more source

CD30 in Systemic Mastocytosis [PDF]

open access: yes, 2014
CD30 is a transmembrane receptor, normally not expressed by mast cells, which regulates proliferation/apoptosis and antibody responses. Aberrant expression of CD30 by mastocytosis mast cells and interaction with its ligand CD30L (CD153) appears to play ...
Joanne N.G. Oude Elberink   +7 more
core   +1 more source

French guidelines for the management of nonadvanced mastocytosis in adults

open access: yesOrphanet Journal of Rare Diseases
Mastocytosis is a rare disease caused by abnormal mast cell accumulation/proliferation in various organs/tissues. Its clinical features exhibit significant variability irrespective of its clinical presentation, classification, global survival or impact ...
Cristina Bulai Livideanu   +5 more
doaj   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

open access: yesAllergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy